Literature DB >> 12955087

High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor.

Céline Galés1, Didier Sanchez, Marc Poirot, Stéphane Pyronnet, Louis Buscail, Daniel Cussac, Lucien Pradayrol, Daniel Fourmy, Sandrine Silvente-Poirot.   

Abstract

The cholecystokinin 2 receptor (CCK2R) increases proliferation of normal and neoplastic gastrointestinal cells and activates various mitogenic signaling pathways when stimulated by gastrin. To study the incidence of permanent activation of this receptor in tumorigenicity, a constitutively active mutant was generated by replacing residue Glu151 in the conserved E/DRY motif by Ala. Expression of the E151A-CCK2R mutant in NIH-3T3 cells causes ligand-independent activation of phospholipase C and ornithine decarboxylase, two enzymes critical for mitogenesis. Strikingly, the constitutive activity of this mutant was associated with dramatic alteration of NIH-3T3 cell morphology, enhanced cell proliferation and invasion. Moreover, injection of cells expressing E151A-CCK2R in nude mice resulted in the development of large and rapidly growing tumors. By contrast, none of these effects was observed with cells expressing the wild-type CCK2R, indicating that the tumorigenic properties of the E151A-CCK2R mutant is the result of its constitutive activation. To date, this is the first report that provides evidence for the high tumorigenic effect of a constitutively active CCK2R mutant, thus raising a potential role of the CCK2R in human cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955087     DOI: 10.1038/sj.onc.1206823

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome.

Authors:  Amandine Alard; Bertrand Fabre; Rodica Anesia; Catherine Marboeuf; Philippe Pierre; Christiane Susini; Corinne Bousquet; Stéphane Pyronnet
Journal:  Mol Cell Biol       Date:  2009-12-22       Impact factor: 4.272

2.  Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion.

Authors:  Michael R Paillasse; Philippe de Medina; Guillaume Amouroux; Loubna Mhamdi; Marc Poirot; Sandrine Silvente-Poirot
Journal:  J Lipid Res       Date:  2009-06-05       Impact factor: 5.922

3.  Coexpression of cholecystokinin-B/gastrin receptor and gastrin gene in human gastric tissues and gastric cancer cell line.

Authors:  Jian-Jiang Zhou; Man-Ling Chen; Qun-Zhou Zhang; Jian-Kun Hu; Wen-Ling Wang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

4.  Bryonolic Acid Blocks Cancer Cell Clonogenicity and Invasiveness through the Inhibition of Fatty Acid: Cholesteryl Ester Formation.

Authors:  Farid Khallouki; Robert Wyn Owen; Sandrine Silvente-Poirot; Marc Poirot
Journal:  Biomedicines       Date:  2018-02-12

5.  Permanent Photodynamic Activation of the Cholecystokinin 2 Receptor.

Authors:  Wen Zhu Tang; Zong Jie Cui
Journal:  Biomolecules       Date:  2020-02-04

6.  CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours.

Authors:  Meike Körner; Beatrice Waser; Jean Claude Reubi; Laurence J Miller
Journal:  J Cell Mol Med       Date:  2009-07-20       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.